Health News Releases

  • Today June 15
Masimo SedLine® Brain Function Monitoring
June 13, 11:50
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
Masimo (https://www.masimo.com/) (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women’s Me
Professor Lee Hae-young during the ESH 2025 symposium in Milan, Italy (Photo: Sky Labs)
June 13, 10:40
Sky Labs Pioneers Future of Cuffless Blood Pressure Monitoring
Sky Labs (https://www.skylabs.io/en), a South Korean digital healthcare startup, captured global attention at the European Society of Hypertension (https://www.eshonline.org/) (ESH) 2025 in Milan, Ita
June 13, 08:53
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW stud
June 13, 08:43
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U
Novotech, a global (CRO) and scientific advisory company, is featured in The Next Frontier, a global
June 11, 15:00
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnol
June 11, 12:05
HistoSonics and Cambridge University Unveil Europe’s First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.histosonics.com&esheet=54271355&newsitemid=20250610200010&lan=en-US&anchor=HistoSonics&index=1&md5=090d8ce66da7672c352
June 11, 09:43
Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 1
June 11, 09:02
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U
June 10, 14:10
China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’
June 10, 09:50
Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research
Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of
Samsung Bioepis (President and CEO: Kyung-Ah Kim) has entered into a license, development and commer
June 09, 11:44
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation (“NIPRO”) for multiple bio
Edison Histotripsy System Procedure for Kidney Tumor Animation
June 08, 13:10
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors
HistoSonics, Inc (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54268467&newsitemid=20250606659747&lan=en-US&anchor=HistoSonics%2C+Inc&index=1&md5=9dd499a
June 08, 11:35
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis.
June 08, 11:20
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been gra
Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC.
June 08, 10:50
QPS Celebrates 30th Anniversary
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chie
June 05, 17:20
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) appl
June 05, 17:10
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLE
June 05, 16:00
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed inj
June 05, 15:35
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidi
June 05, 13:35
Fundhost Selects SS&C to Power Fund Accounting & Registry Services
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2025-Enterprise-Press-Release-0625%26utm_medium%3Dpressreleas
Louis Denis, MD, Chief Medical Officer, Byondis
June 04, 15:15
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation
June 04, 11:40
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com%2F&esheet=54264219&newsitemid=20250603992751&lan=en-US&anchor=Takeda&index=1&md5=06ff112e45cab46a48bacf2cabee3e8
June 04, 10:40
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54263182&newsitemid=20250602546858&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 03, 10:00
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54262852&newsitemid=20250531886517&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 02, 11:25
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.protagonist-inc.com%2F&esheet=54262872&newsitemid=20250531031305&lan=
HistoSonics Non-Invasive Edison Histotripsy System
June 01, 10:30
HistoSonics’ Edison Histotripsy System Gains Great Britain Early Market Access Under Unmet Clinical Needs Authorisation
HistoSonics (https://histosonics.com/), announced today that its Edison Histotripsy System for the non-invasive destruction of liver tumours has been granted controlled early limited market access in
May 30, 10:40
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/
Exterior view of the New Building, Yamanashi Plant
May 29, 15:35
Rigaku Completes New Building at Yamanashi Plant
Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; herei
BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.
May 29, 15:30
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation
May 29, 09:14
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib, a potentially be
Nurse Naomi Oyoe Ohene Oti from Ghana – Winner of Aster Guardians Global Nursing Award 2025 (Photo:
May 28, 16:50
Ghana’s Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000
Nurse Naomi Ohene Oti from Ghana has been named the winner of the Aster Guardians Global Nursing Award 2025, selected from 100,000 applications from 199 countries. An Oncology Nurse Specialist and Hea
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific adv
May 28, 16:00
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug deve
key visual image
May 28, 16:00
Revolutionizing Healthcare: Ubitus and MacKay Memorial Hospital Present AI Robot Collaboration at GTC Taiwan
Ubitus, a global leader in cloud streaming and AI solutions, announced its collaboration with MacKay Memorial Hospital to unveil AI-powered multi-modal medical robots at NVIDIA GTC Taiwan 2025. The pr
May 28, 14:32
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF
May 28, 09:05
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR · Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of
May 28, 08:44
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54259352&newsitemid=20250527716937&lan=en-US&anchor=TSE%3A4
May 27, 17:06
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
The Royal Marsden NHS Foundation Trust (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.royalmarsden.nhs.uk%2F&esheet=54258962&newsitemid=20250527348807&lan=en-US&anchor=The+Roya
May 25, 14:25
BeiGene Presents Pioneering Cancer Research at ASCO 2025 - Redefining Treatment Across Hematology and Solid Tumors
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54258273&newsitemid=20250522213317&lan=en-US&anchor=BeiGene&index=1&md5=b2e553cdb745c6a1895871c2f51
May 23, 13:55
Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
May 23, 11:30
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual M
May 23, 11:30
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
May 23, 10:45
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific adv
May 22, 15:25
Novotech Honored with Triple Win in 2025 Pharmaceutical Technology Excellence Awards
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies, is proud to announce its
May 22, 08:40
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demons
May 18, 15:15
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) te
May 18, 15:00
Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week
May 18, 12:55
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Takeda (TSE: 4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2405847) published data f
May 16, 17:20
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced th
Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Na
May 16, 17:00
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
May 16, 15:00
Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania. The new facility is designed to support biopharma customers with applic
25 per page50 per page75 per page100 per page